In early 2026, the pharmaceutical industry is navigating a complex web of new safety reporting requirements for biological and gene therapies. This has triggered a surge in pharmacovigilance outsourcing, as companies seek to leverage global expertise to monitor drug reactions across diverse populations in real-time. The transition into 2026 is marked by the Indian Central Drugs Standard Control...